TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 9275035

Group type: EXPERIMENTAL
Intervention: CMF (Cyclophosphamide, Methotrexate, and Fluorouracil)
Number of subjects: 589

Group type: EXPERIMENTAL
Intervention: FEC (Fluorouracil, 4' Epirubicin, Cyclophosphamide)
Number of subjects: 589

Group type: EXPERIMENTAL
Intervention: FECMP (Fluorouracil, 4' Epirubicin, Cyclophosphamide, Methotrexate, Prednisone)
Number of subjects: 589

Group type: COMPARATOR
Intervention: CMF/EC
Number of subjects: 589
Study: 7912393

Group type: EXPERIMENTAL
Intervention: Molsidomine (1 mg/h intravenously for 48 h, followed by 16 mg molsidomine by mouth daily for 12 days)
Number of subjects: 4017

Group type: COMPARATOR
Intervention: Placebo (identical to molsidomine treatment)
Number of subjects: 4017

Group type: EXPERIMENTAL
Intervention: Molsidomine
Number of subjects: 4017

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4017
Study: 3142511

Group type: EXPERIMENTAL
Intervention: Terfenadine 120 mg
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 31866092

Group type: EXPERIMENTAL
Intervention: Salvage Radiation Therapy (SRT) ± Salvage Hormone Therapy (SHT) (64.8 Gy of SRT followed by 80 mg bicalutamide and LHRH agonist if BCL fails)
Number of subjects: 210

Group type: COMPARATOR
Intervention: Salvage Hormone Therapy (SHT) (80 mg bicalutamide followed by LHRH agonist in case of BCL failure)
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: SRT ± SHT
Number of subjects: 210

Group type: COMPARATOR
Intervention: SHT
Number of subjects: 210
Study: 30797825

Group type: EXPERIMENTAL
Intervention: STEEP (incremental step heights)
Number of subjects: 45

Group type: COMPARATOR
Intervention: CONTROL (non-training)
Number of subjects: 45
Study: 29116013

Group type: EXPERIMENTAL
Intervention: Dexamethasone (40 mg intravenous injection)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Control group (no dexamethasone)
Number of subjects: 38
Study: 25550188

Group type: EXPERIMENTAL
Intervention: Red orange juice
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Blond orange juice
Number of subjects: 18

Group type: COMPARATOR
Intervention: Water (Control)
Number of subjects: 18
Study: 24180149

Group type: EXPERIMENTAL
Intervention: Dexamethasone prophylactically at induction (group B)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo at induction (group A)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Both groups (A and B)
Number of subjects: 100
Study: 21449786

Group type: COMPARATOR
Intervention: Double placebo (placebo injection plus childhood oral placebo)
Number of subjects: 149

Group type: COMPARATOR
Intervention: Estrogen alone (placebo injection plus childhood oral low-dose estrogen)
Number of subjects: 149

Group type: COMPARATOR
Intervention: Growth hormone alone (growth hormone injection plus childhood oral placebo)
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: Growth hormone-estrogen (growth hormone injection plus childhood oral low-dose estrogen)
Number of subjects: 149

Group type: COMPARATOR
Intervention: Growth hormone treatment (vs. placebo)
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: Growth hormone-estrogen vs. growth hormone alone
Number of subjects: 149
Study: 19692688

Group type: COMPARATOR
Intervention: Letrozole monotherapy
Number of subjects: 6182

Group type: COMPARATOR
Intervention: Tamoxifen followed by Letrozole
Number of subjects: 6182

Group type: COMPARATOR
Intervention: Letrozole followed by Tamoxifen
Number of subjects: 6182
Study: 16388875

Group type: EXPERIMENTAL
Intervention: EQ‐5D
Number of subjects: 285

Group type: EXPERIMENTAL
Intervention: Visual Analogue Scale (VAS)
Number of subjects: 285
Study: 12560406

Group type: EXPERIMENTAL
Intervention: Creatine monohydrate (5 g/d + 2 g of dextrose)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo (7 g of dextrose)
Number of subjects: 28
Study: 11192131

Group type: EXPERIMENTAL
Intervention: Amprenavir (APV) in combination with 2 nucleoside reverse transcriptase inhibitors
Number of subjects: 626

Group type: EXPERIMENTAL
Intervention: Amprenavir (APV)
Number of subjects: 626
Study: 9098860

Group type: EXPERIMENTAL
Intervention: Tuberculin skin test (TST) with > 1.5 cm2 reaction during acute phase
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Intermediate strength PPD inoculation (5 TU)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Stimulation with 0.05 TU/mL of PPD
Number of subjects: 11

Group type: COMPARATOR
Intervention: Control T cells
Number of subjects: 11
Study: 8233534

Group type: EXPERIMENTAL
Intervention: 50 mg diclofenac
Number of subjects: 10

Group type: COMPARATOR
Intervention: Saline
Number of subjects: 10
Study: 3912335

Group type: EXPERIMENTAL
Intervention: Nimesulide 200 mg suppositories
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Diclofenac 100 mg suppositories
Number of subjects: 81

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 81
Study: 29979742

Group type: COMPARATOR
Intervention: $0 incentive
Number of subjects: 8715

Group type: EXPERIMENTAL
Intervention: $1 incentive
Number of subjects: 8715

Group type: EXPERIMENTAL
Intervention: $5 incentive
Number of subjects: 8715

Group type: EXPERIMENTAL
Intervention: $10 incentive
Number of subjects: 8715

Group type: EXPERIMENTAL
Intervention: Active-choice testing
Number of subjects: 8715

Group type: EXPERIMENTAL
Intervention: Opt-out testing
Number of subjects: 8715
Study: 27486293

Group type: EXPERIMENTAL
Intervention: Tooth extraction video
Number of subjects: 64

Group type: COMPARATOR
Intervention: Verbal information and routine warnings
Number of subjects: 64
Study: 23982988

Group type: EXPERIMENTAL
Intervention: 12-week exercise therapy
Number of subjects: 95
Study: 21354934

Group type: EXPERIMENTAL
Intervention: 0.4 mg/kg pentazocine with 1.5 mg/kg propofol
Number of subjects: 81

Group type: COMPARATOR
Intervention: 0.5 mg/kg pentazocine with 1.5 mg/kg propofol
Number of subjects: 81
Study: 18720001

Group type: EXPERIMENTAL
Intervention: Melatonin 3 mg daily for 30 days
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Melatonin 3 mg daily for 8 weeks
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study: 17110021

Group type: EXPERIMENTAL
Intervention: TVT
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: TVT-O
Number of subjects: 72
Study: 15008868

Group type: EXPERIMENTAL
Intervention: EMLA applied on both anterior and posterior surfaces of the ear (Group A)
Number of subjects: 22

Group type: COMPARATOR
Intervention: EMLA applied on only one side of the ear (Group B)
Number of subjects: 22
Study: 11281500

Group type: EXPERIMENTAL
Intervention: Sertraline 50-200 mg/day
Number of subjects: 82
Study: 9393427

Group type: EXPERIMENTAL
Intervention: Mandibular implants
Number of subjects: 2212

Group type: EXPERIMENTAL
Intervention: Maxillary implants
Number of subjects: 2212

Group type: EXPERIMENTAL
Intervention: Implants in bone quality 1
Number of subjects: 2212

Group type: EXPERIMENTAL
Intervention: Implants in bone quality 2
Number of subjects: 2212

Group type: EXPERIMENTAL
Intervention: Implants in bone quality 3
Number of subjects: 2212

Group type: EXPERIMENTAL
Intervention: Implants in bone quality 4
Number of subjects: 2212
Study: 7683190

Group type: EXPERIMENTAL
Intervention: High lipase preparation
Number of subjects: 18
Study: 3116770

Group type: EXPERIMENTAL
Intervention: Intermediate purity factor VIII concentrate (not heat-treated)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Heat-treated concentrates of higher purity
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Heat-treated concentrates of lower purity
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Intermediate purity factor VIII concentrate (heat-treated)
Number of subjects: 46
Study: 282003

Group type: EXPERIMENTAL
Intervention: Simultaneous administration of cytosine arabinoside (Ara-C) 150 mg/m2 and methotrexate (MTX) 40 mg/m2
Number of subjects: 56

Group type: COMPARATOR
Intervention: Sequential administration of cytosine arabinoside (Ara-C) 150 mg/m2 and methotrexate (MTX) 40 mg/m2
Number of subjects: 56
Study: 31994007

Group type: EXPERIMENTAL
Intervention: PEGASUS intervention, a standardised two-stage process for shared decision-making.
Number of subjects: 180

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 180
Study: 30261340

Group type: EXPERIMENTAL
Intervention: Point-of-use adsorptive media water filtration device for arsenic removal
Number of subjects: 371

Group type: COMPARATOR
Intervention: Community water arsenic testing program
Number of subjects: 371

Group type: COMPARATOR
Intervention: Low-range field rapid arsenic testing kit
Number of subjects: 371
Study: 28243855

Group type: EXPERIMENTAL
Intervention: BIS-based propofol dosing
Number of subjects: 60

Group type: COMPARATOR
Intervention: LBW-based propofol dosing
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: BIS-based and LBW-based propofol dosing
Number of subjects: 60
Study: 25844841

Group type: EXPERIMENTAL
Intervention: Low-dose infliximab (3.5 mg/kg)
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Standard-dose infliximab (5 mg/kg)
Number of subjects: 123

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 123
Study: 23820795

Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen (HBO) therapy
Number of subjects: 50

Group type: COMPARATOR
Intervention: Intratympanic (IT) steroid injection
Number of subjects: 50
Study: 21383391

Group type: EXPERIMENTAL
Intervention: Preoperative electroacupuncture (EA) for 30 min at bilateral points (LI4‐LI11, LR3‐ST36, PC6‐TE5) with alternating frequencies of 3 and 15 Hz
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Preoperative electroacupuncture (EA)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Sham transcutaneous electrical nerve stimulation (TENS)
Number of subjects: 22
Study: 19549185

Group type: EXPERIMENTAL
Intervention: Short pulse (SP) VSP Er:YAG laser resurfacing
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Extra-long pulse (XLP) VSP Er:YAG laser resurfacing
Number of subjects: 24
Study: 17159456

Group type: EXPERIMENTAL
Intervention: Olanzapine (8 weeks treatment)
Number of subjects: 32
Study: 15233773

Group type: EXPERIMENTAL
Intervention: Interactive software application
Number of subjects: 52

Group type: COMPARATOR
Intervention: Static web page (Control)
Number of subjects: 52
Study: 11487379

Group type: EXPERIMENTAL
Intervention: Quinapril
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control
Number of subjects: 40
Study: 9763328

Group type: EXPERIMENTAL
Intervention: Scaling and root planing and oral hygiene combined with local controlled drug delivery with tetracycline fibers
Number of subjects: 127

Group type: COMPARATOR
Intervention: Scaling and root planing with oral hygiene instructions
Number of subjects: 127
Study: 7875182

Group type: EXPERIMENTAL
Intervention: meperidine 2 mg.kg‐1 (M)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: meperidine 2 mg.kg‐1 plus midazolam 0.05 mg.kg‐1 (M + M)
Number of subjects: 40
Study: 3213917

Group type: EXPERIMENTAL
Intervention: Isoflurane
Number of subjects: 50

Group type: COMPARATOR
Intervention: Halothane
Number of subjects: 50
Study: 29866205

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Number of subjects: 300

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 300
Study: 28012181

Group type: EXPERIMENTAL
Intervention: 35% trichloroacetic acid (TCA)
Number of subjects: 28

Group type: COMPARATOR
Intervention: 5-aminolaevulinic acid (ALA) photodynamic therapy (PDT)
Number of subjects: 28
Study: 26851256

Group type: EXPERIMENTAL
Intervention: Cyber Friendly Schools Project intervention
Number of subjects: 3382

Group type: EXPERIMENTAL
Intervention: Forms of Bullying Scale (FBS)
Number of subjects: 3382
Study: 23233342

Group type: EXPERIMENTAL
Intervention: Heroin-assisted treatment
Number of subjects: 156
Study: 21820084

Group type: EXPERIMENTAL
Intervention: JTE-607 (0.1 mg/kg/h)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: JTE-607 (0.3 mg/kg/h)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: JTE-607 (0.03 mg/kg/h)
Number of subjects: 9
Study: 18075221

Group type: EXPERIMENTAL
Intervention: Dressing containing 800 mg of plant sterol (PS), 15 g daily for 12 weeks
Number of subjects: 59

Group type: COMPARATOR
Intervention: Placebo dressing without PS
Number of subjects: 59
Study: 17076934

Group type: EXPERIMENTAL
Intervention: tiapride (300 mg/d)
Number of subjects: 299

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 299
Study: 15049438

Group type: EXPERIMENTAL
Intervention: Levosulpiride preparation 1 (25 mg)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Levosulpiride preparation 2 (25 mg)
Number of subjects: 28
Study: 11472859

Group type: EXPERIMENTAL
Intervention: rTMS in the left dorsolateral prefrontal cortex
Number of subjects: 8

Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 8
Study: 9150779

Group type: COMPARATOR
Intervention: Vecuronium 100 micrograms/kg
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Rocuronium 1200 micrograms/kg
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Pancuronium 140 micrograms/kg
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Rocuronium 600 micrograms/kg
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Rocuronium 900 micrograms/kg
Number of subjects: 75
Study: 8236072

Group type: EXPERIMENTAL
Intervention: PEF measurement at two hourly intervals during waking hours for one week
Number of subjects: 273

Group type: COMPARATOR
Intervention: Bronchial challenge test measuring the provocative dose of methacholine producing a 20% fall in FEV1 (PD20)
Number of subjects: 273
Study: 3323648

Group type: EXPERIMENTAL
Intervention: i.v. immunoglobulin G
Number of subjects: 288

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 288
Study: 31862532

Group type: EXPERIMENTAL
Intervention: Health professionals should set an example and not smoke
Number of subjects: 1047

Group type: EXPERIMENTAL
Intervention: Health professionals should provide smoking cessation support
Number of subjects: 1047

Group type: EXPERIMENTAL
Intervention: Hospitals should provide smoking cessation treatments
Number of subjects: 1047

Group type: EXPERIMENTAL
Intervention: Hospitals are role model organizations in compliance with the smoke-free legislation
Number of subjects: 1047

Group type: EXPERIMENTAL
Intervention: Hospitalization is a perfect moment to quit smoking
Number of subjects: 1047

Group type: EXPERIMENTAL
Intervention: Expectations of receiving smoking cessation interventions
Number of subjects: 1047
Study: 29473353

Group type: EXPERIMENTAL
Intervention: Combination group (acupuncture at five mind points + modified kidney qi decoction)
Number of subjects: 180

Group type: COMPARATOR
Intervention: Acupuncture group (simple acupuncture at five mind points)
Number of subjects: 180

Group type: COMPARATOR
Intervention: Herb group (simple modified kidney qi decoction)
Number of subjects: 180
Study: 27059278

Group type: EXPERIMENTAL
Intervention: High amplitude burst SCS
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Low amplitude burst SCS
Number of subjects: 40

Group type: COMPARATOR
Intervention: Tonic SCS
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Overall patient preference
Number of subjects: 40
Study: 25625720

Group type: EXPERIMENTAL
Intervention: Pocket revision (Group A)
Number of subjects: 258

Group type: COMPARATOR
Intervention: No pocket revision (Group B)
Number of subjects: 258

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 258
Study: 23856331

Group type: EXPERIMENTAL
Intervention: AS03-adjuvanted split virion vaccine (3.75 μg HA/AS03)
Number of subjects: 4048

Group type: COMPARATOR
Intervention: Non-adjuvanted vaccine (15 μg HA)
Number of subjects: 4048

Group type: EXPERIMENTAL
Intervention: Both vaccines
Number of subjects: 4048
Study: 20495781

Group type: EXPERIMENTAL
Intervention: Transpyloric feeding (TPF)
Number of subjects: 104

Group type: COMPARATOR
Intervention: Gastric feeding (GF)
Number of subjects: 104
Study: 18386547

Group type: EXPERIMENTAL
Intervention: etoricoxib 120 mg
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: etoricoxib 180 mg
Number of subjects: 49

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: etoricoxib 120 mg and 180 mg
Number of subjects: 49
Study: 16098944

Group type: EXPERIMENTAL
Intervention: Auditory distractor (D) sequence during self-paced tapping
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Isochronous auditory target (T) sequence
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control condition (no auditory distractor)
Number of subjects: 0
Study: 14606782

Group type: EXPERIMENTAL
Intervention: Calcium hydroxide (Ca(OH)2) plus H2O paste
Number of subjects: 140

Group type: COMPARATOR
Intervention: Dry cotton pellet
Number of subjects: 140
Study: 11129710

Group type: EXPERIMENTAL
Intervention: Bio-Skincare (BSC) - 1.2 g
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Mosiguard towelletes with 0.574 g PMD
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Deet (15% diethyl-3-methylbenzamide, Tabard lotion) - 0.5 g
Number of subjects: 3

Group type: COMPARATOR
Intervention: Untreated control (right arm)
Number of subjects: 3
Study: 8770963

Group type: EXPERIMENTAL
Intervention: Magnesium carbonate (MgCO3) at a dose of 465 +/- 52 mg/day elemental Mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Calcium carbonate (CaCO3) at the usual dose
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Magnesium carbonate (MgCO3)
Number of subjects: 0
Study: 1443141

Group type: EXPERIMENTAL
Intervention: Transmucosal electrical nerve stimulation (15 Hz, 100 microseconds)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Mechanical stimuli (balloon distension)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Jejunal slow wave activity
Number of subjects: 12
Study: 2857677

Group type: EXPERIMENTAL
Intervention: Somatostatin infusion for 72 hours
Number of subjects: 95

Group type: COMPARATOR
Intervention: Placebo infusion
Number of subjects: 95
Study: 30785624

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy for BDD (CBT‐BDD)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Supportive Psychotherapy
Number of subjects: 120
Study: 29477262

Group type: EXPERIMENTAL
Intervention: Type D personality
Number of subjects: 180
Study: 27393697

Group type: EXPERIMENTAL
Intervention: Basal insulin peglispro (BIL)
Number of subjects: 455

Group type: COMPARATOR
Intervention: Insulin glargine (GL)
Number of subjects: 455
Study: 24914425

Group type: EXPERIMENTAL
Intervention: Mechanical tooth cleaning by toothbrush and dental floss once a day
Number of subjects: 54

Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 54
Study: 22897549

Group type: EXPERIMENTAL
Intervention: Enhanced services funded by the AFL program
Number of subjects: 1038

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 1038
Study: 20420943

Group type: EXPERIMENTAL
Intervention: 2 ng/kg Escherichia coli endotoxin (LPS)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 17659062

Group type: EXPERIMENTAL
Intervention: MST plus standard care (SC)
Number of subjects: 127

Group type: COMPARATOR
Intervention: Standard care (SC) alone
Number of subjects: 127
Study: 16089135

Group type: EXPERIMENTAL
Intervention: Conventional medicine plus tongxinluo capsule (TXL)
Number of subjects: 112

Group type: COMPARATOR
Intervention: Conventional medicine (Control Group)
Number of subjects: 112
Study: 12017350

Group type: EXPERIMENTAL
Intervention: Rivastigmine treatment
Number of subjects: 2791

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2791
Study: 10084583

Group type: EXPERIMENTAL
Intervention: 1 mg oral estradiol daily
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: 2 mg oral estradiol daily
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study: 7745019

Group type: EXPERIMENTAL
Intervention: Soy-supplemented diet for 4 weeks
Number of subjects: 97

Group type: COMPARATOR
Intervention: Control group (instructed to eat as usual)
Number of subjects: 97
Study: 2166619

Group type: EXPERIMENTAL
Intervention: Dexon Plus
Number of subjects: 84

Group type: COMPARATOR
Intervention: Maxon
Number of subjects: 84
Study: 7195483

Group type: EXPERIMENTAL
Intervention: Bromocriptine and domperidone
Number of subjects: 20

Group type: COMPARATOR
Intervention: Domperidone (control for nausea and vomiting)
Number of subjects: 20
Study: 31847908

Group type: EXPERIMENTAL
Intervention: 0.1% topical sirolimus applied for 12 weeks
Number of subjects: 55

Group type: COMPARATOR
Intervention: Topical vehicle applied for 12 weeks
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Systemic passage of sirolimus measured at weeks 6, 12, and 20, and at week 16 for CMLMs ≥ 900 cm2
Number of subjects: 55
Study: 30084133

Group type: EXPERIMENTAL
Intervention: New York University Caregiver Intervention (NYUCI)
Number of subjects: 221

Group type: EXPERIMENTAL
Intervention: REACH‐OUT
Number of subjects: 221
Study: 26265727

Group type: EXPERIMENTAL
Intervention: Efalex Active 50+ (1g DHA, 160 mg eicosapentaenoic acid, 240 mg Ginkgo biloba, 60 mg phosphatidylserine, 20mg d‐α tocopherol, 1mg folic acid, and 20 µg vitamin B12 per day)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study: 24443035

Group type: EXPERIMENTAL
Intervention: Duty-cycled multi-electrode radiofrequency ablation (PVAC)
Number of subjects: 161

Group type: COMPARATOR
Intervention: Conventional irrigated point-by-point radiofrequency ablation (CPVI)
Number of subjects: 161
Study: 22522786

Group type: EXPERIMENTAL
Intervention: Muscle strengthening exercises (performed twice a week for 3 months, starting at 60% of 1MR and progressing to 85%)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Control group (no exercise)
Number of subjects: 58
Study: 18469366

Group type: EXPERIMENTAL
Intervention: Healthy Youth Places (HYP) intervention
Number of subjects: 1582

Group type: COMPARATOR
Intervention: Control group (non-HYP schools)
Number of subjects: 1582
Study: 17635424

Group type: EXPERIMENTAL
Intervention: Reverse manoeuvre for inserting the Airtraq laryngoscope
Number of subjects: 40

Group type: COMPARATOR
Intervention: Standard technique for inserting the Airtraq laryngoscope
Number of subjects: 40
Study: 15159711

Group type: EXPERIMENTAL
Intervention: 3 guideline implementation strategies of increasing intensity
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Best practices including assessment of arterial oxygenation, collection of blood cultures, timely initiation of appropriate empiric antibiotic therapy
Number of subjects: 0
Study: 11861264

Group type: EXPERIMENTAL
Intervention: IFN-alpha plus LDAC
Number of subjects: 538

Group type: COMPARATOR
Intervention: IFN-alpha
Number of subjects: 538
Study: 10211597

Group type: EXPERIMENTAL
Intervention: PEIT-1 (1 session with a single intranodular injection of sterile 98% ethanol)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: PEIT-3 (3 weekly sessions with 1 injection of sterile 98% ethanol)
Number of subjects: 60